TRIBUNNEWS.COM – Takeda Pharmaceutical Company Limited (Takeda) announces the candidate dengue fever vaccine dengue (DHF) Takeda (TAK-003) is able to prevent dengue disease up to 62 percent.
After going through a series of trials of tetravalent immunization against DHF phase 3 (TIDES Phase 3), the candidate for the TAK-003 vaccine was stated to be able to reduce the risk of patient hospitalization by up to 83.6 percent, without the risk of other health problems for the next three years after immunization.
“The trial of tetravalent immunization against DHF phase 3 (TIDES Phase 3) involved more than 20,000 healthy children and adolescents aged 4 to 16 years, in dengue endemic countries in Asia and Latin America. We are optimistic that the TAK-003 vaccine candidate can help overcome the problem of dengue fever in the world,” said Derek Wallace, Vice President of Dengue Global Program Leader at Takeda Pharmaceutical, which was released in Osaka, Japan, today, Friday (28/5/2021).
Dengue fever is a viral disease that spreads quickly through mosquitoes.
Dengue fever became one of the WHO’s top 10 threats to global health in 2019. The options for preventing this disease are still limited to date.
Also read: Beware of dengue fever, water reservoirs have the potential to become mosquito nests
In Indonesia, throughout 2020, dengue cases were recorded at 95,893 cases, with the number of deaths reaching 661 people.
Dengue cases are spread across 472 districts/cities in 34 provinces. Deaths due to DHF occurred in 219 districts/cities.
The TIDES trial is Takeda’s largest intervention clinical trial.
This clinical trial involves an independent Data Monitoring Committee, which consists of experts who actively monitor the safety of trial participants on an ongoing basis.
Further exploration of the TIDES phase 3 trial was carried out for 36 months. The results of this exploration were presented last week (22/5/2021), at the 17th International Society of Travel Medicine (CISTM) Conference in Kuala Lumpur, Malaysia.
–
